Korean J Hematol.  2011 Sep;46(3):164-168. 10.5045/kjh.2011.46.3.164.

ABO-incompatible renal transplantation: From saline flushes to antigen-specific immunoadsorption-Tools to overcome the barrier

Affiliations
  • 1Department of Nephrology, Hannover Medical School, Hannover, Germany. Kielstein@yahoo.com

Abstract

On April 23, 1951, a 30-year-old woman received the first intentional ABOi (ABO incompatible) renal transplantation in Boston. At that time, it was commonly believed that intensely rinsing the graft to remove blood would be sufficient to overcome any immunological problems associated with blood type incompatibility. However, when the abovementioned patient and another ABOi transplant recipient died within a month, Humes and colleagues arrived at the same conclusion: "We do not feel that renal transplantation in the presence of blood incompatibility is wise." In the decades that followed, we learned that the oligosaccharide surface antigens representing the ABO-blood group antigens are expressed not only on erythrocytes but also on cells from various tissues, including the vascular endothelium. The growing gap between organ demand and availability has sparked efforts to overcome the ABO barrier. After its disappointing results in the early 1970s, Japan became the leader of this endeavor in the 1980s. All protocols are based on 2 strategies: removal of preformed antibodies with extracorporeal techniques and inhibition of ongoing antibody production. Successful ABOi renal transplantation became possible with the advent of splenectomy, new immunosuppressive drugs (e.g., rituximab, a monoclonal antibody against CD20), and extracorporeal methods such as antigen-specific immunoadsorption. This review summarizes the underlying pathophysiology of ABOi transplantation and the different protocols available. Further, we briefly touch potential short- and long-term problems, particularly the incidence of infectious complications and malignancies, that can arise with high-intensity immunosuppressive therapy.

Keyword

Graft survival; Graft loss; Rejection; Preconditioning

MeSH Terms

Adult
Antibodies
Antibodies, Monoclonal, Murine-Derived
Antibody Formation
Antigens, Surface
Boston
Endothelium, Vascular
Erythrocytes
Female
Graft Survival
Humans
Incidence
Japan
Kidney Transplantation
Rejection (Psychology)
Splenectomy
Transplants
Rituximab
Antibodies
Antibodies, Monoclonal, Murine-Derived
Antigens, Surface

Figure

  • Fig. 1 Hyperacute rejection mediated by ABO antibodies. Preformed natural antibodies bind to blood group carbohydrate structures on endothelial cells. This leads to complement fixation, microthrombosis and microhemorrhages.


Reference

1. Kantha SS. The blood revolution initiated by the famous footnote of Karl Landsteiner's 1900 paper. Ceylon Med J. 1995; 40:123–125. PMID: 8536328.
2. Yamamoto F, McNeill PD, Hakomori S. Genomic organization of human histo-blood group ABO genes. Glycobiology. 1995; 5:51–58. PMID: 7772867.
Article
3. Reed E, Moore BP. A new variant of blood group A. Vox Sang. 1964; 9:363–366. PMID: 14170906.
Article
4. Sturgeon P, Moore BP, Weiner W. Notations for two weak a variants: AEND and AEL. Vox Sang. 1964; 9:214–215. PMID: 14147442.
Article
5. Economidou J, Hughes-Jones NC, Gardner B. Quantitative measurements concerning A and B antigen sites. Vox Sang. 1967; 12:321–328. PMID: 6067900.
6. Andersson M, Carlin N, Leontein K, Lindquist U, Slettengren K. Structural studies of the O-antigenic polysaccharide of Escherichia coli O86, which possesses blood-group B activity. Carbohydr Res. 1989; 185:211–223. PMID: 2471591.
Article
7. Hardy RR, Hayakawa K. CD5 B cells, a fetal B cell lineage. Adv Immunol. 1994; 55:297–339. PMID: 7508175.
Article
8. Hanto DW, Brunt EM, Goss JA, Cole BR. Accelerated acute rejection of an A2 renal allograft in an O recipient: association with an increase in anti-A2 antibodies. Transplantation. 1993; 56:1580–1583. PMID: 8305085.
9. Ruggeri ZM. von Willebrand factor. J Clin Invest. 1997; 99:559–564. PMID: 9045854.
Article
10. Sodetz JM, Paulson JC, McKee PA. Carbohydrate composition and identification of blood group A, B, and H oligosaccharide structures on human Factor VIII/von Willebrand factor. J Biol Chem. 1979; 254:10754–10760. PMID: 315409.
Article
11. Matsui T, Shimoyama T, Matsumoto M, et al. ABO blood group antigens on human plasma von Willebrand factor after ABO-mismatched bone marrow transplantation. Blood. 1999; 94:2895–2900. PMID: 10515894.
Article
12. Hume DM, Merrill JP, Miller BF, Thorn GW. Experiences with renal homotransplantation in the human: report of nine cases. J Clin Invest. 1955; 34:327–382. PMID: 13233354.
13. Cook DJ, Graver B, Terasaki PI. ABO incompatibility in cadaver donor kidney allografts. Transplant Proc. 1987; 19:4549–4552. PMID: 3321616.
14. Starzl TE, Marchioro TL, Holmes JH, et al. Renal homografts in patients with major donor-recipient blood group incompatibilities. Surgery. 1964; 55:195–200. PMID: 14121762.
15. Alexandre GP, Squifflet JP, De Bruyère M, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc. 1987; 19:4538–4542. PMID: 3321614.
16. Tanabe K. Japanese experience of ABO-incompatible living kidney transplantation. Transplantation. 2007; 84(12 Suppl):S4–S7. PMID: 18162988.
Article
17. Bier M, Beavers CD, Merriman WG, Merkel FK, Eiseman B, Starzl TZ. Selective plasmapheresis in dogs for delay of heterograft response. Trans Am Soc Artif Intern Organs. 1970; 16:325–333. PMID: 4916739.
18. Bensinger WI, Buckner CD, Thomas ED, Clift RA. ABO-incompatible marrow transplants. Transplantation. 1982; 33:427–429. PMID: 7041368.
Article
19. Slapak M, Naik RB, Lee HA. Renal transplant in a patient with major donor-recipient blood group incompatibility: reversal of acute rejection by the use of modified plasmapheresis. Transplantation. 1981; 31:4–7. PMID: 7015598.
20. Garonzik Wang JM, Montgomery RA, Kucirka LM, Berger JC, Warren DS, Segev DL. Incompatible live-donor kidney transplantation in the United States: results of a national survey. Clin J Am Soc Nephrol. 2011; 6:2041–2046. PMID: 21784826.
Article
21. Ichimaru N, Takahara S. Japan's experience with living-donor kidney transplantation across ABO barriers. Nat Clin Pract Nephrol. 2008; 4:682–692. PMID: 18941430.
Article
22. Tobian AA, Shirey RS, Montgomery RA, Ness PM, King KE. The critical role of plasmapheresis in ABO-incompatible renal transplantation. Transfusion. 2008; 48:2453–2460. PMID: 18657072.
Article
23. Tanabe K. Double-filtration plasmapheresis. Transplantation. 2007; 84(12 Suppl):S30–S32. PMID: 18162985.
Article
24. Bensinger WI, Buckner CD, Williams B, Clift RA. Immune adsorption of anti-A and anti-B antibodies. Prog Clin Biol Res. 1982; 88:295–300. PMID: 7048329.
25. Bensinger WI, Buckner CD, Baker DA, Clift RA, Thomas ED. Removal of specific antibody in vivo by whole blood immunoadsorption: preliminary results in dogs. J Clin Apher. 1982; 1:2–5. PMID: 6765452.
Article
26. Schneider KM. Plasmapheresis and immunoadsorption: different techniques and their current role in medical therapy. Kidney Int Suppl. 1998; 64:S61–S65. PMID: 9475492.
27. Habicht A, Bröker V, Blume C, et al. Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experience. Nephrol Dial Transplant. 2011; [Epub ahead of print].
Article
28. Tydén G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigenspecific immunoadsorption and rituximab. Transplantation. 2003; 76:730–731. PMID: 12973118.
Article
29. Wilpert J, Fischer KG, Pisarski P, et al. Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. Nephrol Dial Transplant. 2010; 25:3778–3786. PMID: 20466677.
Article
30. Schwenger V, Morath C. Immunoadsorption in nephrology and kidney transplantation. Nephrol Dial Transplant. 2010; 25:2407–2413. PMID: 20472578.
Article
31. Shatney CH. Complications of splenectomy. Acta Anaesthesiol Belg. 1987; 38:333–339. PMID: 3327338.
32. Tobian AA, Shirey RS, Montgomery RA, Ness PM, King KE. The critical role of plasmapheresis in ABO-incompatible renal transplantation. Transfusion. 2008; 48:2453–2460. PMID: 18657072.
Article
33. Montgomery RA, Cooper M, Kraus E, et al. Renal transplantation at the Johns Hopkins Comprehensive Transplant Center. Clin Transpl. 2003; 199–213. PMID: 15387112.
34. Takahashi K. Accommodation in ABO-incompatible kidney transplantation: why do kidney grafts survive. Transplant Proc. 2004; 36(Suppl 2):193S–196S. PMID: 15041335.
Article
35. Setoguchi K, Ishida H, Shimmura H, et al. Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation. Am J Transplant. 2008; 8:86–94. PMID: 18021283.
Article
36. Tanabe M, Shimazu M, Wakabayashi G, et al. Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation. 2002; 73:1959–1961. PMID: 12131697.
37. Saliba F, Ichaï P, Azoulay D, et al. Successful long-term outcome of ABO-incompatible liver transplantation using antigen-specific immunoadsorption columns. Ther Apher Dial. 2010; 14:116–123. PMID: 20438529.
Article
38. Strüber M, Warnecke G, Hafer C, et al. Intentional ABOincompatible lung transplantation. Am J Transplant. 2008; 8:2476–2478. PMID: 18808407.
Article
39. Valli PV, Puga Yung G, Fehr T, et al. Changes of circulating antibody levels induced by ABO antibody adsorption for ABO-incompatible kidney transplantation. Am J Transplant. 2009; 9:1072–1080. PMID: 19344433.
Article
40. Genberg H, Kumlien G, Wennberg L, Berg U, Tydén G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation. 2008; 85:1745–1754. PMID: 18580466.
Article
Full Text Links
  • KJH
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr